Shares of Synergy Pharmaceuticals (SGYP) Drops by -12.38%

Synergy Pharmaceuticals (SGYP) : During the past 4 weeks, traders have been relatively bearish on Synergy Pharmaceuticals (SGYP), hence the stock is down -5.24% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -13.67% relative to the S&P 500. The 4-week change in the price of the stock is -1.1% and the stock has fallen -12.38% in the past 1 week. The stock has recorded a 20-day Moving Average of 5.31% and the 50-Day Moving Average is 1.36%.

Synergy Pharmaceuticals (NASDAQ:SGYP): The stock opened at $3.50 on Friday but the bulls could not build on the opening and the stock topped out at $3.67 for the day. The stock traded down to $3.35 during the day, due to lack of any buying support eventually closed down at $3.61 with a loss of -5.74% for the day. The stock had closed at $3.83 on the previous day. The total traded volume was 5,048,085 shares.


The company Insiders own 3.6% of Synergy Pharmaceuticals shares according to the proxy statements. Institutional Investors own 35.73% of Synergy Pharmaceuticals shares. In a related news,The officer (Senior Vice President, Finance) of Synergy Pharmaceuticals, Inc., Denoyer Bernard sold 10,000 shares at $7.5 on September 14, 2015. The Insider selling transaction had a total value worth of $75,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *